EYE DISORDERS CONGENITAL
Clinical trials for EYE DISORDERS CONGENITAL explained in plain language.
Never miss a new study
Get alerted when new EYE DISORDERS CONGENITAL trials appear
Sign up with your email to follow new studies for EYE DISORDERS CONGENITAL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye drug aims to halt blindness in rare genetic disease
Disease control Recruiting nowThis study tests a drug called ultevursen in people with retinitis pigmentosa caused by changes in a specific part of the USH2A gene. The drug is injected into the eye and is designed to slow the loss of vision over two years. The trial includes 81 adults and children aged 8 and …
Matched conditions: EYE DISORDERS CONGENITAL
Phase: PHASE2 • Sponsor: Laboratoires Thea • Aim: Disease control
Last updated May 17, 2026 07:54 UTC
-
Experimental drug aims to restore sight in rare childhood blindness
Disease control Recruiting nowThis study tests an investigational drug called sepofarsen in people with Leber congenital amaurosis (LCA), a rare genetic eye disease that causes severe vision loss from birth. The trial includes 32 participants aged 6 and older who have a specific mutation in the CEP290 gene. E…
Matched conditions: EYE DISORDERS CONGENITAL
Phase: PHASE3 • Sponsor: Laboratoires Thea • Aim: Disease control
Last updated May 13, 2026 15:59 UTC